Tharimmune, Inc. — Director's Dealing 2022

Jan 11, 2022

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Hillstream BioPharma Inc. (HILS)
CIK: 0001861657
Period of Report: 2022-01-11

Reporting Person: Appajosyula Sireesh (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common stock	284090	Direct
Common stock	972222	Indirect
Common stock	75757	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Options (right to purchase)	$0.0792	2024-08-30	Common stock (37878)		Direct

Footnotes

F1: The shares of common stock are owned by Highpoint Pharmaceuticals LLC. Sireesh Appajosyula is the Managing Member of Highpoint Pharmaceuticals LLC and in such capacity has the right to vote and dispose of the securities held by such entity.

F2: The shares of common stock are owned by Mercer Lake Group LLC. Sireesh Appajosyula is the is the Managing Member of Mercer Lake Group LLC and in such capacity has the right to vote and dispose of the securities held by such entity.

F3: The Registrant issued the Reporting Person the options on August 30, 2019. The options vested immediately upon grant and become exercisable upon (i) consummation of the Registrant's initial public offering of its securities or (ii) consummation of a reverse merger of the Registrant with and into a public company.